ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS MARKET ANALYSIS

Acute Bacterial Skin And Skin Structure Infections Market Size and Trends

Global acute bacterial skin and skin structure infections market is estimated to be valued at USD 3,842.5 Mn in 2024 and is expected to reach USD 5,701.7 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.8% from 2024 to 2031.

To learn more about this report, request sample copy

There has been increase in prevalence of acute bacterial skin and skin structure infections worldwide due to changing lifestyles and environmental conditions.  The market growth is driven by increasing number of surgical procedures that require post-operative infection management. Rising geriatric population prone to such infections further drive the market growth.

 Increasing Product Launches by Key Market Players

Market players are involved in launching new drugs, and this is expected to drive growth of the global acute bacterial skin and skin structure infections market over the forecast period. For instance, on July 7, 2021, Melinta Therapeutics, a pharmaceutical company, launched its product- KIMYRSA. KIMYRSA is a lipoglycopeptide antibiotic that provide a complete course of treatment for acute bacterial skin and skin structure infections. KIMYRSA is effective in a single dose of 1200mg injection.

One of the key drivers fueling growth of global acute bacterial skin and skin structure infections market is rising prevalence of various types of skin infections across both developed and developing regions. Skin and soft tissue infections include a wide range of conditions that affect the epidermis and soft tissues just below the skin. These infections can range from relatively minor and superficial infections to serious and even life-threatening deep infections. Cellulitis is one of the most common acute bacterial skin infections characterized by diffuse swelling and inflammation of the deep layers of the skin and subcutaneous tissues. According to various studies, the global incidence of cellulitis is estimated to be between 33 to 126 cases per 100,000 population per year. The rate of hospitalization due to cellulitis has also increased significantly over the last decade. Increasing prevalence of cellulitis can primarily be attributed to factors such as aging population, rising incidence of diabetes - a major risk factor, and increased microbial resistance. Similarly, wound and surgical site infections are also becoming more common globally due to growing number of surgeries and invasive procedures performed every year.